📰 David Penake News
David Penake News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Penake. Real-time updates on events, politics, business and more.
March 16, 2023
/PRNewswire/ -- Saol Therapeutics ("Saol"), a privately held, clinical-stage pharmaceutical company, announced today the signing of an agreement with Medosome...
October 4, 2022
/PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the pivotal Phase 3 clinical trial evaluating...
August 9, 2022
/PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the...
May 3, 2022
Topline Data Expected in 2023ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, May 3, 2022 /PRNewswire/ -- Saol Therapeutics, a privately held, clini...
January 5, 2022
05.01.2022 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal and ... Seite 1
December 7, 2021
/PRNewswire/ -- Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saols LYVISPAH™ (baclofen) oral granules....
December 7, 2021
/PRNewswire/ -- Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saols LYVISPAH™ (baclofen) oral granules....
February 8, 2021
Search jobs 08-Feb-2021 “Rare Voices” Podcast Series Continues: Optime Care Further Explores Unique Perspectives of Exceptional People Reshaping Patient Experiences With Rare & Orphan Diseases EARTH CITY, Mo.--(BUSINESS WIRE)--#rarediseases--Optime Care, a nationally recognized pharmacy, specialty distributor and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, is pleased to anno...